Viva Biotech climbs 6%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Viva Biotech (1873.HK) climbed more than 6% in Hong Kong trading to HK$1.34.

The stock is down 25.56% year to date and sits 28.85% above its 52-week low of HK$1.040.

The Hang Seng Index is down 2.33% over the past five sessions and down 9.87% year to date.

The life sciences tools and services industry index rose 3.2% over the same period; the stock outperformed the index by 3.1 percentage points.

Guosen Securities initiated coverage on the company with a Buy rating, forecasting revenue of 2.054 billion yuan, 2.535 billion yuan and 3.13 billion yuan for 2026 through 2028, respectively. Net income is projected at 191 million yuan, 261 million yuan and 353 million yuan over the same period.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.